中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2008年
11期
728-732
,共5页
张丽红%王慧君%张莉%周康%杨栋林%阎璋松%李洪强%刘庆国%齐军元%刘强%储榆林%张凤奎
張麗紅%王慧君%張莉%週康%楊棟林%閻璋鬆%李洪彊%劉慶國%齊軍元%劉彊%儲榆林%張鳳奎
장려홍%왕혜군%장리%주강%양동림%염장송%리홍강%류경국%제군원%류강%저유림%장봉규
贫血,再生障碍性%彗星试验%电泳,琼脂凝胶%遗传不稳定性%免疫抑制治疗
貧血,再生障礙性%彗星試驗%電泳,瓊脂凝膠%遺傳不穩定性%免疫抑製治療
빈혈,재생장애성%혜성시험%전영,경지응효%유전불은정성%면역억제치료
Anemia,aplastic%Comet assay%Electrophoresis,agar gel%Genetic instability%Immunosuppressive therapy
目的 研究强烈免疫抑制治疗(IST)对再生障碍性贫血(AA)患者骨髓细胞遗传不稳定性的影响.方法 采用彗星试验检测患者骨髓细胞遗传不稳定性,以彗星尾部DNA(TDNA)百分比、尾长(TL)、尾矩(TM)、Olive尾矩(OTM)和彗星细胞率作为分析参数,分别检测IST前后AA患者骨髓细胞,并与对照组结果比较.结果 91例初治从患者TDNA百分比、TL、TM、OTM、彗星细胞率分别为(5.0±4.0)%、11.3±7.2、1.7±2.0、1.5±1.4、(16.8±13.7)%,明显高于对照组(P值均<0.05);58例重型AA(SAA)与33例非重型AA(NSAA)患者彗星试验各项参数比较差异均无统计学意义(P值均>0.05),二组患者各彗星试验参数与对照组比较,差异均有统计学意义(P值均<0.05).53例SAA患者治疗后3个月TDNA百分比、TL、TM、OTM、彗星细胞率分别为(4.4±3.6)%、10.4±7.5、0.4±1.6、1.3±1.4、(20.2±21.2)%,30例SAA患者治疗后6个月TDNA百分比、TL、TM、OTM、彗星细胞率分别为(3.7±3.3)%、10.0±7.2、1.2±1.8、1.1±1.3、(18.5±19.0)%,结果与58例SAA患者IST前彗星参数比较差异均无统计学意义(P值均>0.05).结论 AA患者骨髓细胞存在遗传不稳定性,IST本身近期并不增加SAA患者细胞遗传不稳定性.提示IST与从患者发生晚期克隆性血液学异常可能无关.
目的 研究彊烈免疫抑製治療(IST)對再生障礙性貧血(AA)患者骨髓細胞遺傳不穩定性的影響.方法 採用彗星試驗檢測患者骨髓細胞遺傳不穩定性,以彗星尾部DNA(TDNA)百分比、尾長(TL)、尾矩(TM)、Olive尾矩(OTM)和彗星細胞率作為分析參數,分彆檢測IST前後AA患者骨髓細胞,併與對照組結果比較.結果 91例初治從患者TDNA百分比、TL、TM、OTM、彗星細胞率分彆為(5.0±4.0)%、11.3±7.2、1.7±2.0、1.5±1.4、(16.8±13.7)%,明顯高于對照組(P值均<0.05);58例重型AA(SAA)與33例非重型AA(NSAA)患者彗星試驗各項參數比較差異均無統計學意義(P值均>0.05),二組患者各彗星試驗參數與對照組比較,差異均有統計學意義(P值均<0.05).53例SAA患者治療後3箇月TDNA百分比、TL、TM、OTM、彗星細胞率分彆為(4.4±3.6)%、10.4±7.5、0.4±1.6、1.3±1.4、(20.2±21.2)%,30例SAA患者治療後6箇月TDNA百分比、TL、TM、OTM、彗星細胞率分彆為(3.7±3.3)%、10.0±7.2、1.2±1.8、1.1±1.3、(18.5±19.0)%,結果與58例SAA患者IST前彗星參數比較差異均無統計學意義(P值均>0.05).結論 AA患者骨髓細胞存在遺傳不穩定性,IST本身近期併不增加SAA患者細胞遺傳不穩定性.提示IST與從患者髮生晚期剋隆性血液學異常可能無關.
목적 연구강렬면역억제치료(IST)대재생장애성빈혈(AA)환자골수세포유전불은정성적영향.방법 채용혜성시험검측환자골수세포유전불은정성,이혜성미부DNA(TDNA)백분비、미장(TL)、미구(TM)、Olive미구(OTM)화혜성세포솔작위분석삼수,분별검측IST전후AA환자골수세포,병여대조조결과비교.결과 91례초치종환자TDNA백분비、TL、TM、OTM、혜성세포솔분별위(5.0±4.0)%、11.3±7.2、1.7±2.0、1.5±1.4、(16.8±13.7)%,명현고우대조조(P치균<0.05);58례중형AA(SAA)여33례비중형AA(NSAA)환자혜성시험각항삼수비교차이균무통계학의의(P치균>0.05),이조환자각혜성시험삼수여대조조비교,차이균유통계학의의(P치균<0.05).53례SAA환자치료후3개월TDNA백분비、TL、TM、OTM、혜성세포솔분별위(4.4±3.6)%、10.4±7.5、0.4±1.6、1.3±1.4、(20.2±21.2)%,30례SAA환자치료후6개월TDNA백분비、TL、TM、OTM、혜성세포솔분별위(3.7±3.3)%、10.0±7.2、1.2±1.8、1.1±1.3、(18.5±19.0)%,결과여58례SAA환자IST전혜성삼수비교차이균무통계학의의(P치균>0.05).결론 AA환자골수세포존재유전불은정성,IST본신근기병불증가SAA환자세포유전불은정성.제시IST여종환자발생만기극륭성혈액학이상가능무관.
Objective To investigate the impact of immunosuppressive therapy(IST) on genetic in-stabilities of bone marrow hematopoietic cells (BMHCs) in patients with aplastic anemia(AA). Methods Comet assay as used to detect genetic instabilities of hematopoietic ceils from patients, and the percent of DNA in comet tail (TDNA), tail length(TL), tail moment(TM), olive tail moment(OTM) and the rate of comet cells were measured. BMHCs from AA patients were examined with comet assay before and after IST, and the results were compared with those from controls. Results Comet parameters from 91 AA patients in-cluding TDNA, TL, TM, OTM comet cell percentage were (5.0 ± 4.0) %, 11.3 ± 7.2, 1.7 ± 2.0, 1.5 ± 1.4, (16.8 ± 13.7)%, respectively, which were significandy higher than those from control group (P < 0.05). There were statistical differences between the comet parameters of severe AA(SAA)/non-SAA (NSAA) and those of control group(P <0.05), but no difference in the comet parameters between SAA and NSAA patients(P>0.05). The TDNA, TL, TM, OTM and comet cells percentage were (4.4±3.6)%, 10.4 ± 7.5, 1.4 ± 1.6, 1.3 ± 1.4 and (20.2 ± 21.2) %, respectively at 3 months after [ST in 53 SAA pa-tients and were (3.7 ± 3.3) %, 10.0 ± 7.2, 1.2 ± 1.8, 1.1 ± 1.3 and (18.5 ± 19.0) % respectively at 6 months after IST in 30 SAA patients, being no statistical difference from those of 58 SAA patients before IST (P values were all > 0. 05). Conclusion B MHCs of AA had inherent genetic instabilities which were not increased by recent IST. It indicated that there was no correlation between LST and the development of clonal hematologic disorders in AA.
